BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Sold by Fox Run Management L.L.C.

Fox Run Management L.L.C. lessened its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 42.8% in the 4th quarter, Holdings Channel reports. The fund owned 8,216 shares of the biotechnology company’s stock after selling 6,150 shares during the period. Fox Run Management L.L.C.’s holdings in BioMarin Pharmaceutical were worth $540,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in BMRN. KLP Kapitalforvaltning AS purchased a new position in BioMarin Pharmaceutical during the fourth quarter worth about $4,387,000. Sector Gamma AS raised its stake in shares of BioMarin Pharmaceutical by 14.2% during the 4th quarter. Sector Gamma AS now owns 217,348 shares of the biotechnology company’s stock worth $14,286,000 after buying an additional 27,000 shares in the last quarter. Blueshift Asset Management LLC acquired a new stake in shares of BioMarin Pharmaceutical in the 4th quarter valued at approximately $349,000. Teacher Retirement System of Texas boosted its stake in shares of BioMarin Pharmaceutical by 121.2% in the fourth quarter. Teacher Retirement System of Texas now owns 112,660 shares of the biotechnology company’s stock valued at $7,405,000 after buying an additional 61,737 shares in the last quarter. Finally, Xponance Inc. grew its holdings in BioMarin Pharmaceutical by 7.6% during the fourth quarter. Xponance Inc. now owns 31,675 shares of the biotechnology company’s stock worth $2,082,000 after acquiring an additional 2,247 shares during the period. Hedge funds and other institutional investors own 98.71% of the company’s stock.

BioMarin Pharmaceutical Stock Performance

Shares of BMRN stock opened at $71.53 on Wednesday. BioMarin Pharmaceutical Inc. has a one year low of $60.63 and a one year high of $94.85. The company has a 50 day moving average price of $66.83 and a 200 day moving average price of $67.78. The firm has a market capitalization of $13.65 billion, a price-to-earnings ratio of 32.51, a price-to-earnings-growth ratio of 0.61 and a beta of 0.33. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.62 and a current ratio of 5.33.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.54 by $0.18. The firm had revenue of $747.31 million during the quarter, compared to the consensus estimate of $711.05 million. BioMarin Pharmaceutical had a return on equity of 9.91% and a net margin of 14.96%. Sell-side analysts anticipate that BioMarin Pharmaceutical Inc. will post 3.15 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Citigroup raised their price objective on shares of BioMarin Pharmaceutical from $81.00 to $82.00 and gave the company a “neutral” rating in a research note on Thursday, February 20th. Oppenheimer upgraded BioMarin Pharmaceutical from a “market perform” rating to an “outperform” rating and set a $98.00 price target on the stock in a report on Monday, February 24th. StockNews.com raised BioMarin Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Tuesday, March 18th. Royal Bank of Canada reissued a “sector perform” rating and issued a $70.00 target price on shares of BioMarin Pharmaceutical in a report on Thursday, February 20th. Finally, UBS Group lifted their price target on BioMarin Pharmaceutical from $109.00 to $113.00 and gave the stock a “buy” rating in a research note on Thursday, February 20th. Seven research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, BioMarin Pharmaceutical currently has a consensus rating of “Moderate Buy” and a consensus target price of $94.00.

Insider Buying and Selling

In other BioMarin Pharmaceutical news, CAO Erin Burkhart sold 1,295 shares of the business’s stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $71.52, for a total transaction of $92,618.40. Following the completion of the sale, the chief accounting officer now directly owns 16,955 shares in the company, valued at $1,212,621.60. The trade was a 7.10 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.85% of the company’s stock.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.